Prevalance of heparin-dependent platelet-activating antibodies in preterm newborns after exposure to unfractionated heparin.
Heparin is frequently used in preterm infants to prolong the patency of intravascular catheters. The aim of this study was to evaluate the prevalence of heparin-dependent platelet-activating antibodies in newborns. A cross-section of all preterm newborn infants expected to require heparin to maintain patency of a central venous access line were enrolled. A blood sample was obtained soon after birth before heparin exposure to exclude the possibility of placental transfer of maternal heparin-dependent platelet-activating antibodies. A second sample was obtained at termination of heparin use (mean duration of heparin exposure was 23 +/- 13 days; range, 6-67). Paired samples, at birth and after heparin use, were available for 42 infants with a mean gestational age of 27.8 +/- 2.2 weeks and birth weight of 1036 +/- 267 g. Thrombocytopenia developed in 57% (24/42) of the infants. None of these infants had clinical suspicion of thrombosis during the study period. The etiology of thrombocytopenia was confirmed sepsis in six, presumed sepsis in three, necrotizing enterocolitis in one, and unclear in 14 infants. Anti-heparin/platelet factor 4 antibodies measured using the standard assays for heparin-induced thrombocytopenia (two commercially available enzyme-linked immunosorbent assay tests and the functional platelet serotonin release assay) were negative on all infants. Although it could be related to the poor ability of these infants to mount an immunologic response, further research is necessary to fully understand this lack of response to heparin and to elucidate further the reasons for thrombocytopenia in very-low-birth-weight infants.
Kumar
Praveen
P
Pediatrics, Northwestern Memorial Hospital, Chicago, Illinois, USA. p-kumar@northwestern.edu
Hoppensteadt
Debra A
DA
Prechel
M Margaret
MM
Deddish
Ruth B
RB
Walenga
Jeanine M
JM
D001323:Autoantibodies / Q000097:blood*; D001792:Blood Platelets / Q000276:immunology*; D002405:Catheterization, Central Venous / Q000009:adverse effects / Q000379:methods; D003430:Cross-Sectional Studies; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D006493:Heparin / Q000009:adverse effects* / Q000276:immunology; D006801:Humans; D007231:Infant, Newborn; D007234:Infant, Premature / Q000097:blood*; D008297:Male; D010976:Platelet Count; D010978:Platelet Factor 4 / Q000276:immunology; D015995:Prevalence; D018805:Sepsis / Q000150:complications; D013921:Thrombocytopenia / Q000209:etiology
D001323:Autoantibodies; D010978:Platelet Factor 4; D006493:Heparin